Clinical trials: Glioma, Malignant
Glioblastoma Multiforme, Chemoradiation
Simultaneous Integrated Boost in Malignant Glioma Patients Treated With Chemoradiation
Simultaneous integrated boost (SIB), a field-in-field escalation technique, has been introduced to deliver higher radiation dose to the certain part of target with the same fractionation scheme.
- Trial name
- NCT03225300
- Testing
- Simultaneous integrated boost
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Taichung Veterans General Hospital
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG
The goal of this study is to further evaluate feasibility and tolerability of Opdualag for patients with replication repair deficient HGG, including DIPG.
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
- Trial name
- NCT07644312
- Testing
- Opdualag
- Volunteers
- 12 people
- Sponsor
- Nationwide Children's Hospital
Glioma, Hematopoietic and Lymphoid Cell Neoplasm
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction.
- Conditions
- Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT01638533
- Testing
- Pharmacological Study, Romidepsin
- Where
- 12 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Glioma
Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma
Malignant gliomas are very aggressive and among the most common of brain tumors. A diagnosis carries with it a median survival of approximately 12 months, with 90 - 95% of patients surviving less than 2 years.
- Trial name
- NCT01235845
- Testing
- Biological: DC activated CIK combined with DC
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Qingdao University
Brain and Central Nervous System Tumors
Karenitecin in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of karenitecin in treating patients who have recurrent…
- Trial name
- NCT00014521
- Testing
- karenitecin
- Where
- 8 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Malignant Gliomas
Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy
Malignant gliomas are aggressive tumours with poor prognosis despite the current multimodal treatment. Hence, there is a clear need for new, effective therapies, among which immune therapy has emerged as a promising treatment…
- Trial name
- NCT01657734
- Testing
- MR imaging
- Where
- 2 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Glioblastoma, Malignant Glioma
FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma
This phase I trial tests the safety, side effects, best dose and how well FPS-ZM1 works for controlling post operative cerebral edema in patients with glioblastoma.
- Conditions
- Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma
- Trial name
- NCT07791264
- Testing
- Biospecimen Collection, Computed Tomography, Dexamethasone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center
High-grade Glioma
Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study
1. To retrospectively explore the feasibility of multi-dimensional heterogeneity imaging features of MRI in predicting the status of key gene mutations in high-grade gliomas; 2.
- Trial name
- NCT06002711
- Testing
- MR scanning; Clinical data collection
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- RenJi Hospital
Glioma, Astrocytoma
Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)
The purpose of this study is to confirm the safety and efficacy of temozolomide in patients with newly diagnosed malignant glioma (concomitant with radiotherapy and then as monotherapy) and relapsed malignant glioma (as…
- Trial name
- NCT00705198
- Testing
- Temozolomide (for newly diagnosed malignant glioma), Temozolomide (for relapsed malignant glioma), Radiotherapy (for patients with newly diagnosed malignant glioma)
- Volunteers
- 1,804 people
- Sponsor
- Merck Sharp & Dohme LLC
Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity
Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors
RATIONALE: Learning whether temozolomide changes semen or sperm in patients with brain tumors may help doctors learn about the long-term effects of treatment and plan the best treatment.
- Conditions
- Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity, Infertility
- Trial name
- NCT00499798
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Recurrent Childhood Medulloblastoma, Recurrent Ependymoma
Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors
This phase I trial studies the side effects and best dose of expanded natural killer cells in treating younger patients with brain tumors that have come back or do not respond to treatment.
- Conditions
- Recurrent Childhood Medulloblastoma, Recurrent Ependymoma, Recurrent Medulloblastoma
- Trial name
- NCT02271711
- Testing
- Laboratory Biomarker Analysis, Natural Killer Cell Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer, Breast Cancer
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
This project utilizes LRRC15-specific targeted PET radiotracers to perform PET/MR or PET/CT imaging on healthy volunteers and patients with clinically suspected or confirmed malignancies characterized by high LRRC15…
- Conditions
- Pancreatic Cancer, Breast Cancer, Lung Cancer, Sarcoma
- Trial name
- NCT07552467
- Testing
- Specific PET imaging agents targeting LRRC15
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Recurrent Ependymoma, Recurrent Ewing Sarcoma
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors, including central nervous system tumors, lymphomas and histiocytic disorders that have not responded to (refractory) or…
- Conditions
- Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis
- Trial name
- NCT04195555
- Testing
- Ivosidenib
- Where
- 174 sites in United States, Australia and 1 more
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, GBM
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
The goal of this Phase 3 clinical trial is to compare the efficacy of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma multiforme (GBM).
- Conditions
- Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor
- Trial name
- NCT06388733
- Testing
- Niraparib, Temozolomide
- Where
- 95 sites in United States, Australia and 9 more
- Volunteers
- 450 people
- Sponsor
- Ivy Brain Tumor Center
Malignant Glioma of Brain, Astrocytoma
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent…
- Conditions
- Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Brain Tumor
- Trial name
- NCT05686798
- Testing
- Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Henry Ford Health System
Glioblastoma, Malignant Glioma
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma
This phase I trial tests the safety, side effects, and best dose of dexamethasone when given with azeliragon in managing cerebral edema after surgery (post-resection) in patients with glioblastoma.
- Trial name
- NCT05773664
- Testing
- Azeliragon, Biospecimen Collection, Computed Tomography
- Sponsor
- City of Hope Medical Center
Brain Tumor, Medulloblastoma
WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors
In this Phase I clinical study, the investigators plan to offer investigational treatment with the novel JAK2/STAT3 inhibitor WP1066 (Moleculin Biotech, Inc.) to pediatric patients with any progressive or recurrent malignant…
- Conditions
- Brain Tumor, Medulloblastoma, Brain Metastases
- Trial name
- NCT04334863
- Testing
- WP1066
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Glioma, Glioma, Malignant
Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)
This single center, single arm, open-label, phase I study will assess the safety of a laparoscopically harvested omental free flap into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.
- Conditions
- Glioma, Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme
- Trial name
- NCT04222309
- Testing
- Laparoscopically harvested omental free flap
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Glioblastoma Multiforme, Cytomegalovirus Infection
Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection
The purpose of this study is to investigate if treatment of CMV infection by antiviral drug Valcyte (R) affects the clinical outcome of glioblastoma multiforme in patients with local CMV infection in tumor tissue.
- Trial name
- NCT00400322
- Testing
- Valganciclovir (Valcyte)
- Where
- 3 sites in Sweden
- Volunteers
- 42 people
- Sponsor
- Karolinska Institutet
Glioblastoma
ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma
The purpose of this study is to test WSD0628 in combination with radiation therapy for recurrent brain tumors.
- Trial name
- NCT05917145
- Testing
- WSD0628
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.